[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=C][Branch2][Ring2][=C][C][Branch2][Ring1][O][C][=Branch1][Branch2][=C][Branch1][Ring2][N][Ring1][=Branch1][C][C][=Branch1][C][=O][O][C][/C][=C][/C][=C][C][=C][C][=C][Ring1][=Branch1][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N+1][=Branch1][C][=O][O-1][C][=Branch1][C][=O][O][C][C][O][C]"}, {"from": "gpt", "value": "The molecule is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. This drug is approved in China, Japan, Korea, India, and several countries in the European Union."}]